$DHR News

Danaher Is Getting Better, But The Stock Still Isn't Cheap

Jim Cramer on Danaher: “I Don’t Want You Anywhere Near That One”

Danaher (DHR) Wins CE Mark For Access P Tau217 Assay, Is The Stock A Bargain?

VTRS or DHR: Which Is the Better Value Stock Right Now?

Beckman Coulter Diagnostics Expands Alzheimer's Portfolio with CE-Marked p-Tau217 Blood Test and New High-Specificity Research Assay

Evercore ISI Group Maintains Outperform on Danaher, Lowers Price Target to $230

What to Expect From Danaher's Next Quarterly Earnings Report

Danaher Foundation Commits $1 Million to Ebola Outbreak Relief Efforts in Central Africa

Danaher: Why I'm Not Paying 24x P/E For 8% EPS Growth

Danaher (DHR) Completes $9.9B Acquisition of Masimo Corporation

Danaher (DHR) Stock Is Up, What You Need To Know

Danaher (DHR) Stock Weighs Mixed Valuation Signals After Recent Price Rebound

Danaher (DHR) Crossed Above the 20-Day Moving Average: What That Means for Investors

Is Danaher (DHR) Using Masimo’s New FDA-Cleared AI Tool To Redefine Its Medtech Edge?

HSBC Cuts PT on Danaher Corporation (DHR) – Here’s Why

VTRS vs. DHR: Which Stock Is the Better Value Option?

Danaher Schedules Second Quarter 2026 Earnings Conference Call

Masimo Receives FDA Clearance For Opioid-Induced Respiratory Depression Detection Capability Combined Into Its Radius VSM

Medtech M&A maintains momentum following decade-high 2025: PwC

IDBS and Alchemi partner to accelerate biopharma regulatory filings with compliant AI agents